Alprazolam / Sertraline Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 0.25mg + 25mg
Reference Brands: Various Indian Brand Available
Category:
Antipsychotropic Drugs
Alprazolam + Sertraline is a combination of two medicines: Alprazolam and Sertraline, which has anxiety-lowering and mood-enhancing effects. Alprazolam is a benzodiazepine (BZD) which increases the action of GABA, a chemical messenger that suppresses the abnormal activity of the nerve cells in the brain. Sertraline is selective serotonin reuptake inhibitor (SSRI) which increases the levels of serotonin, a chemical messenger that improves mood.
Alprazolam / Sertraline Tablet is available in Tablets
and strengths such as 0.25mg + 25mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alprazolam / Sertraline Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alprazolam / Sertraline Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
A 12-week, placebo-controlled outpatient study was conducted to evaluate the efficacy and safety of sertraline hydrochloride and alprazolam in patients diagnosed with panic disorder, with and without agoraphobia, according to ICD-10 criteria. The study included 40 adult patients aged 18 years and above, who were randomly assigned to receive either sertraline or alprazolam in fixed doses.
Sertraline was administered at a dose of 20 mg per day, while alprazolam was given in doses ranging from 1 to 1.5 mg per day. The evaluation focused on key clinical parameters, including the frequency of panic attacks, severity of agoraphobia, and levels of anticipatory anxiety.
The results demonstrated that both sertraline and alprazolam significantly reduced the frequency of panic attacks in patients with panic disorder. In addition, notable improvements were observed in symptoms of agoraphobia and anticipatory anxiety. These findings highlight the effectiveness of both medications in managing panic disorder, with each offering therapeutic benefits in reducing acute anxiety symptoms and improving overall patient outcomes when used under appropriate medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing